Annotation inferences using phylogenetic trees
Gene Ontology annotation based on curation of immunofluorescence data
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours.
Self-assembling protein microarrays.
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.
The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells.
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases.
Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function.
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases.
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells.
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3.
CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
Functional characterization of human PFTK1 as a cyclin-dependent kinase.
Sulindac suppresses beta-catenin expression in human cancer cells.
Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription.
UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes.
Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest.
Crystal structure of human CDK4 in complex with a D-type cyclin.
Isolation and characterization of cytoplasmic cyclin D1 mutants.
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage.
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
TM4SF5 accelerates G1/S phase progression via cytosolic p27Kip1 expression and RhoA activity.
C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression.
Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility.
Next-generation sequencing to generate interactome datasets.
NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor.
Toward an understanding of the protein interaction network of the human liver.
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS.
Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway.
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
A proteome-scale map of the human interactome network.
A massively parallel pipeline to clone DNA variants and examine molecular phenotypes of human disease mutations.
Widespread macromolecular interaction perturbations in human genetic disorders.
A human interactome in three quantitative dimensions organized by stoichiometries and abundances.
Pooled-matrix protein interaction screens using Barcode Fusion Genetics.
Architecture of the human interactome defines protein communities and disease networks.
Structural basis of the phosphorylation-independent recognition of cyclin D1 by the SCF(FBXO31) ubiquitin ligase.
A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.
The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.
CRL4(AMBRA1) is a master regulator of D-type cyclins.
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
A protein interaction landscape of breast cancer.
A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Multimodal cell maps as a foundation for structural and functional genomics.
F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression.
Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C.
Growth suppression by p16ink4 requires functional retinoblastoma protein.
Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
Cyclin-binding motifs are essential for the function of p21CIP1.
New functional activities for the p21 family of CDK inhibitors.
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins.
Cyclin D:Cdk4/6 mediated phosphorylation of p130 (RBL2) and dissociation of phosphorylated p130 (RBL2) from DP1:E2F4/5 complex
Cyclin D:CDK4/6 mediated phosphorylation of p107 (RBL1) and dissociation of phosphorylated p107 (p-RBL1) from DP1:E2F4 complex
CDK4 in CCND1:CDK4:PRMT5:WDR77 phosphorylates WDR77
COPRS binds CCND1:CDK4:PRMT5:pT5-WDR77
CCND1:CDK4:PRMT5:pT5-WDR77 methylates arginine-9 of histone H3 (H3R8)
COPRS:CCND1:CDK4:PRMT5:pT5-WDR77 methylates arginine-4 of histone H4 (H4R3)
PRMT5:pT5-WDR77 methylates arginine-4 of histone H2A (H2AR3)
CCND1:CDK4:PRMT5:pT5-WDR77 methylates methyl-arginine-9 of histone H3
Expression of STAT3-upregulated nuclear proteins
Cyclin D:CDK4/6 phosphorylates RB1 and prevents RB1 binding to E2F1/2/3:DP1/2 complexes
Relocalization of nuclearly localized phospho-(T286):cyclin D1:Cdk4 to cytoplasm
Relocalization of nuclearly localized Cyclin D1 to the cytoplasm
Ubiquitination of Cyclin D1
Proteasome mediated degradation of Cyclin D1
Activated PTK6 binds CDKN1B
PTK6 phosphorylates CDKN1B
Expression of CCND1 is stimulated by CTNNB1:TCF4,LEF1 and inhibited by VENTX:TCF4,LEF1
Formation of CDK4/6:CCND complexes
Cip/Kip CDK inhibitors bind CDK4/6:CCND complexes
Tyrosine kinases phosphorylate Cip/Kip inhibitors bound to CDK4/6:CCND complexes
Translocation of CDK4/6:CCND complexes from the cytoplasm to the nucleus
CDK4/6:CCND complexes are activated by T-loop phosphorylation of CDK4/6
Expression of CCND1 is stimulated by CTNNB1:TCF4,LEF1
CCND1 binds RUNX3 and displaces EP300
CCND1 recruits HDAC4 to RUNX3
CDK4 phosphorylates RUNX2
Estrogen-responsive CCND1 gene expression
ESR1-dependent CCND1 expression
CDK6 inhibitors bind CDK6
CDK4 inhibitors bind CDK4
MITF-M and CTNNB1-dependent CCND1 expression
CDK4:CCND1 phosphorylates SPOP
Falcon deep research report for CCND1